EMEliza Mathias Melo

Eliza Mathias Melo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eliza Mathias Melo has a total of 59 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of a recombinant influenza virus carrying interleukin 7 gene as a platform for novel immunotherapeutic approaches

    by Sarah Giarola da Silva Messias, Ianca Évelin Silva de Paula, Kimberly Freitas Cardoso, Cristiana Couto Garcia, Ana Luiza Pessoa de Mendonça Ângelo, Ana Paula de Faria Gonçalves, Eliza Mathias Melo, Luciana Pádua Tavares, Lídia Paula Faustino, Pedro Augusto Alves, et al.

  • Open Access

    CXCR2 antagonism as a promising therapeutic approach for pulmonary fibrosis therapy

    by Eliza Mathias Melo, Filipe Resende, Fernando Roque Ascenção, Celso Martins Queiroz-Junior, Mario Amatruda, Mara Tomassetti, Laura Brandolini, Gianluca Bianchini, Andrea Aramini, Frederico Marianetti Soriani, et al.


  • Angiotensin-(1-7) treatment improves pneumonia and prevents sepsis caused by pneumococcal infection

    by Eliza Mathias Melo, Izabela Galvão, Franciel Batista Felix, Fernanda Medeiros Vale Magalhães, Flavia Rago, Marina Gomes Machado, Fernando Roque Ascenção, Maria José Campagnole-Santos, Robson Augusto Souza dos Santos, Geovanni Dantas Cassali, et al.

    Background Pneumonia caused by Streptococcus pneumoniae remains a major global health concern, leading to significant morbidity and mortality. Angiotensin-(1-7) [Ang-(1-7)] is an endogenous peptide with known anti-inflammatory and pro-resolving properties, but its therapeutic potential in bacterial pneumonia is not fully understood. Purpose This study aimed to investigate whether Ang-(1-7) could reduce inflammation, improve bacterial clearance, and enhance survival in a murine model of pneumococcal pneumonia, alone or in combination with the antibiotic ceftriaxone. Methods A mouse model of S. pneumoniae pneumonia was used to evaluate the effects of Ang-(1-7). Mice received Ang-(1-7) treatment after infection, either alone or combined with ceftriaxone. Outcomes included leukocyte infiltration, pulmonary edema, lung tissue damage, cytokine production (TNF-α, IL-6, CXCL-1), bacterial load in bronchoalveolar lavage and blood, survival analysis, bone marrow-derived macrophage phagocytosis assays, and expression of lung barrier–associated genes. Results Ang-(1-7) reduced leukocyte infiltration, pulmonary edema, and lung tissue injury, and decreased pro-inflammatory cytokine levels. Treatment improved bacterial clearance in both lungs and bloodstream and increased survival in infected mice. Importantly, combining Ang-(1-7) with ceftriaxone further enhanced survival, even when treatment initiation was delayed. Mechanistically, Ang-(1-7) increased macrophage phagocytic activity and upregulated genes associated with lung barrier integrity. Conclusion Ang-(1-7) decreased inflammation, improved bacterial clearance, and enhanced survival in severe pneumococcal pneumonia. Its combination with ceftriaxone produced additive benefits, supporting Ang-(1-7) as a promising adjuvant therapeutic strategy in this infectious condition


  • Open Access

    Plasmin and plasminogen prevent sepsis severity by reducing neutrophil extracellular traps and systemic inflammation

    by Juliana P. Vago, Isabella Zaidan, Luiza O. Perucci, Larissa Froede Brito, Lívia C.R. Teixeira, Camila Meirelles Souza Silva, Thaís C. Miranda, Eliza M. Melo, Alexandre S. Bruno, Celso Martins Queiroz-Junior, et al.

    Sepsis is a lethal syndrome characterized by systemic inflammation and abnormal coagulation. Despite therapeutic advances, sepsis mortality remains substantially high. Herein, we investigated the role of the plasminogen/plasmin (Plg/Pla) system during sepsis. Plasma levels of Plg were significantly lower in mice subjected to severe compared with nonsevere sepsis, whereas systemic levels of IL-6, a marker of sepsis severity, were higher in severe sepsis. Plg levels correlated negatively with IL-6 in both septic mice and patients, whereas plasminogen activator inhibitor-1 levels correlated positively with IL-6. Plg deficiency render mice susceptible to nonsevere sepsis induced by cecal ligation and puncture (CLP), resulting in greater numbers of neutrophils and M1 macrophages, liver fibrin(ogen) deposition, lower efferocytosis, and increased IL-6 and neutrophil extracellular trap (NET) release associated with organ damage. Conversely, inflammatory features, fibrin(ogen), and organ damage were substantially reduced, and efferocytosis was increased by exogenous Pla given during CLP- and LPS-induced endotoxemia. Plg or Pla protected mice from sepsis-induced lethality and enhanced the protective effect of antibiotics. Mechanistically, Plg/Pla–afforded protection was associated with regulation of NET release, requiring Pla-protease activity and lysine binding sites. Plg/Pla are important host-protective players during sepsis, controlling local and systemic inflammation and collateral organ damage.